Table 2.
Univariate and multivariable analyses (logistic regression) of factors responsible for switch to triple therapy
| Response | Effect | Odds ratio estimate | 95 CI | |
|---|---|---|---|---|
| Univariate analysis | ||||
| Switch to TRIPLE | Randomized treatment: FP/SAL vs TIO | 0.840 | 0.559 | 1.263 |
| GOLD patient category 1: C and D vs A and B | 4.011 | 2.520 | 6.383 | |
| GOLD patient category 2: B and D vs A and C | 1.790 | 1.145 | 2.796 | |
| Eosinophil: ≥2% vs <2% | 0.756 | 0.395 | 1.445 | |
| Sex: female vs male | 2.907 | 1.160 | 7.287 | |
| Age: 65–74 vs 18–64 years | 3.181 | 1.774 | 5.706 | |
| Age: ≥75 vs 18–64 years | 4.081 | 2.030 | 8.205 | |
| Smoking history: current smoker vs former smoker | 0.751 | 0.493 | 1.144 | |
| RS-subscale breathlessness: mean baseline | 1.229 | 1.152 | 1.311 | |
| RS-subscale cough and sputum: mean baseline | 1.213 | 1.067 | 1.379 | |
| RS-subscale chest symptoms: mean baseline | 1.399 | 1.242 | 1.575 | |
| Multivariable analysis | ||||
| Switch to TRIPLE | Randomized treatment (FP/SAL vs TIO) | 0.952 | 0.603 | 1.504 |
| GOLD group (C and D vs A and B) | 3.362 | 2.047 | 5.523 | |
| Age 65–74 vs 18–64 years | 2.862 | 1.539 | 5.323 | |
| Age ≥75 vs 18–64 years | 3.141 | 1.485 | 6.643 | |
| RS-subscale chest symptoms (baseline) | 1.371 | 1.208 | 1.555 |
Abbreviations: FP/SAL, fluticasone propionate/salmeterol; GOLD, Global initiative for chronic Obstructive Lung Disease 2011 criteria; RS, respiratory symptoms; TIO, tiotropium.